Answers are grounded in this paper and cite their sources.
• UL50 deletion markedly attenuates ILTV pathogenicity in chickens • Chickens inoculated with the UL50-deleted ILTV exhibited no detectable viral shedding or viral replication in the trachea. • Full UL50 deletion compromises protective efficacy against virulent challenge • UL50 is an important virulence determinant but complete removal causes over-attenuation • Optimized UL50-based attenuation may improve safety–efficacy balance of ILTV vaccines Infectious laryngotracheitis virus (ILTV) causes severe respiratory disease in chickens and remains a major concern for poultry production. Although live-attenuated vaccines are widely used, residual virulence and latency raise safety concerns. The UL50 gene encodes a conserved deoxyuridine triphosphatase (dUTPase) and has been implicated in herpesvirus virulence, but its value as a vaccine attenuation target in ILTV remains uncertain. Here, we evaluated the effects of complete UL50 ORF deletion on the pathogenicity and immunogenicity of ILTV in chickens to assess its potential as a target for developing safer live-attenuated ILTV vaccines. Four-day-old chickens were inoculated via the eye-drop or intranasal route to evaluate pathogenicity and protective efficacy against challenge with the virulent SH2016 strain. The rGD2018-ΔUL50 exhibited further attenuation, inducing only minimal clinical signs and showing no detectable viral shedding or viral replication in the larynx and trachea. In contrast, the parental low-virulence GD2018 strain caused slightly more evident mild clinical signs. Despite its marked attenuation, the UL50-deleted strain conferred partial protection against challenge, whereas GD2018-inoculated chickens were fully protected. These results indicate that UL50 plays an important role in ILTV virulence, and that its complete deletion leads to over-attenuation, compromising protective efficacy. Optimization of UL50-based attenuation strategies, such as partial modification or combination with other genetic approaches, may facilitate the development of safer and effective next-generation ILTV live vaccines.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: